BML-190

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
BML-190
BML-190.svg
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC23H23ClN2O4
Molar mass426.892 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

BML-190 (Indomethacin morpholinylamide) is a drug used in scientific research that acts as a selective CB2 inverse agonist.[1] BML-190 is structurally derived from the NSAID indomethacin but has a quite different biological activity.[2] The activity produced by this compound is disputed, with some sources referring to it as a CB2 agonist rather than an inverse agonist;[3][4] this may reflect an error in classification, or alternatively it may produce different effects in different tissues, and more research is required to resolve this dispute.

Lead optimization of the parent structure resulted in L-768,242 & L-759,787.

References[edit]

  1. ^ New, DC; Wong, YH (2003). "BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates". FEBS Letters. 536 (1–3): 157–60. doi:10.1016/S0014-5793(03)00048-6. PMID 12586356.
  2. ^ Klegeris, A; Bissonnette, CJ; McGeer, PL (2003). "Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor". British Journal of Pharmacology. 139 (4): 775–86. doi:10.1038/sj.bjp.0705304. PMC 1573900. PMID 12813001.
  3. ^ Melck, D; De Petrocellis, L; Orlando, P; Bisogno, T; Laezza, C; Bifulco, M; Di Marzo, V (2000). "Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation". Endocrinology. 141 (1): 118–26. doi:10.1210/en.141.1.118. PMID 10614630.
  4. ^ Scutt, A; Williamson, EM (2007). "Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors". Calcified Tissue International. 80 (1): 50–9. doi:10.1007/s00223-006-0171-7. PMID 17205329.